Skip to content
Screener

Pacira BioSciences, Inc. PCRX Q2 2025 earnings

Reported August 5, 2025 · After market close

Revenue$181.1MMiss by $1.3M
EPS$0.74Beat by $0.02
Revenue estimate$182.4M
EPS estimate$0.72

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$182.2M
EPS estimate$0.76

Financials

Q2 2025

Income statement

See full
Revenue$181.1M+1.7%
Gross profit$140.2M+4.8%
Operating income$8.5M-69.9%
Net income-$4.8M-126%
EPS (diluted)-$0.11-128%

Balance sheet

See full
Cash & equivalents$300.5M+21.6%
Total debt$351.1M+108%
Total equity$757.8M-13.8%
Total assets$1.5B-6.7%

Cash flow

See full
Operating cash flow$12.0M-77.4%
CapEx$2.7M+69.6%
Free cash flow$9.3M-82.0%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.14B-14.3%
Enterprise value$1.19B-4.9%
P/S1.6×-0.3×

Profitability

See full
Gross margin78.2%+4.1pp
FCF margin16.6%-10.2pp

Returns & leverage

See full
Debt / equity0.5×+0.3×
Current ratio2.4×-4.4×

Segments

By product

See full
EXPAREL$142.9M+4.4%
ZILRETTA$31.3M+2.0%
iovera°$5.6M-1.5%
Bupivacaine liposome injectable suspension$508.0K-83.9%

By segment

See full
Reportable Segment$181.1M+1.7%

FAQ

When did Pacira BioSciences, Inc. report Q2 2025 earnings?
Pacira BioSciences, Inc. (PCRX) reported Q2 2025 earnings on August 5, 2025 after market close.
What were Pacira BioSciences, Inc.'s Q2 2025 revenue and EPS?
Pacira BioSciences, Inc. reported revenue of $181.1M and eps of $0.74 for Q2 2025.
Did Pacira BioSciences, Inc. beat estimates in Q2 2025?
Revenue missed the consensus estimate of $182.4M by $1.3M. EPS beat the consensus estimate of $0.72 by $0.02.
How did Pacira BioSciences, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 1.7% from $178.0M a year earlier and eps declined 16.9% from $0.89.
Where can I find Pacira BioSciences, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0001396814-25-000100) and the 10-Q periodic report (0001396814-25-000102) directly on SEC EDGAR. The filing index links above go to sec.gov.